Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
Submitted by
admin
on March 29, 2017 - 4:56pm
Source:
Marketwatch
News Tags:
Mylan Labs
FDA
generics
asthma
GSK
Advair Diskus
Headline:
Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
Do Not Allow Advertisers to Use My Personal information
